Meta-analysis of studies with genome sequencing in myelodysplastic syndrome treated with hypomethylating agents
Nikolay U. Tcvetkov,Olga S. Epifanovskaya,Yulia V. Rudnitskaya,Elena V. Morozova,Ivan S. Moiseev,Boris V. Afanasyev +5 more
- 25 Mar 2018
- Vol. 7, Iss: 1, pp 44-51
TL;DR: Meta-analysis of studies with genome sequencing in myelodysplastic syndrome treated with hypomethylating agents Cellular Therapy and Transplantation (CTT) shows clear trends in survival and morbidity in patients treated with these agents.
read more
Abstract: Nikolay U. Tcvetkov, Olga S. Epifanovskaya, Yulia V. Rudnitskaya, Elena V. Morozova, Ivan S. Moiseev, Boris V. Afanasyev R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia Meta-analysis of studies with genome sequencing in myelodysplastic syndrome treated with hypomethylating agents Cellular Therapy and Transplantation (CTT). Vol. 7, No. 1(22), 2018 doi: 10.18620/ctt-1866-8836-2018-7-1-44-51 Submitted: 26 March 2018, accepted: 27 April 2018
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy
Magnus Tobiasson,Donal P. McLornan,Mohsen Karimi,Marios Dimitriou,Monika Jansson,Asmaa Ben Azenkoud,Martin Jädersten,Greger Lindberg,Hani Abdulkadir,Austin G. Kulasekararaj,Johanna Ungerstedt,Andreas Lennartsson,Karl Ekwall,Ghulam J. Mufti,Eva Hellström-Lindberg +14 more
TL;DR: It is believed that survival is the most relevant endpoint, supported by the fact that even non-responding patients have a survival benefit from Azacitidine, and both karyotype and mutational profile were strongly associated with survival from the start of treatment.
23
Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors
Daisuke Ikeda,SungGi Chi,Satoshi Uchiyama,Hirotaka Nakamura,Yong-Mei Guo,Nobuhiko Yamauchi,Junichiro Yuda,Yosuke Minami +7 more
TL;DR: Clinical data suggest that adverse genetic factors can be found in at least one in eight AML patients and appear to accumulate in relapsed/refractory cases and TP53 mutation is associated with particularly poor prognosis.
16
High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome.
Ivan S. Moiseev,Nikolay Yurevich Tcvetkov,Ildar M. Barkhatov,Maria V. Barabanshikova,Dmitrii Sergeevich Bug,Natalya Vitalievna Petuhova,Artem Tishkov,E.A. Bakin,Ekaterina Andreevna Izmailova,Alena I. Shakirova,Alexandr Dmitrievich Kulagin,Elena V. Morozova +11 more
TL;DR: In this paper, the authors performed a pilot study which evaluated mutational burden in these genes and their association with common myelodysplastic syndrome (MDS) mutations and found that high prevalence of mutations was observed in the genes studied: 54% had mutations in DICER1, 46% had mutated in LAG3, 20% in CTLA4, 23% in B7-H3, 17% in DROSHA, 14% in PD-1 and 3% in PPD-1L.
Myelodysplastic Syndromes (MDS) Display a Risk and Senescence-Dependent MicroRNA (miRNA) Signature.
Lubomir Sokol,Myka Estes,Ann H. Williams,Yukiyasu Ozawa,Stefano Volinia,Chang Gong Liu,Carlo M. Croce,Alan F. List +7 more
TL;DR: The miRNA microarray profile of MDS BM-MNC with normal controls was compared, and differences by Northern blot and real-time RT-PCR were validated, suggesting altered regulation of miRNA expression in hematopoietic progenitors plays a critical role in the physiology of hematobiology senescence and in MDS pathogenesis.
1
References
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil,Moritz Gerstung,Lars Bullinger,Verena I. Gaidzik,Peter Paschka,Nicola D. Roberts,Nicola E. Potter,Michael Heuser,Felicitas Thol,Niccolo Bolli,Gunes Gundem,Peter Van Loo,Inigo Martincorena,Peter Ganly,Laura Mudie,Stuart McLaren,Sarah O’Meara,Keiran Raine,David R. Jones,Jon W. Teague,Adam Butler,Mel Greaves,Arnold Ganser,Konstanze Döhner,Richard F. Schlenk,Hartmut Döhner,Peter J. Campbell +26 more
TL;DR: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification.
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg,Heinz Tuechler,Julie Schanz,Guillermo Sanz,Guillermo Garcia-Manero,Francesc Solé,John M. Bennett,David T. Bowen,Pierre Fenaux,François Dreyfus,Hagop M. Kantarjian,Andrea Kuendgen,Alessandro Levis,Luca Malcovati,Mario Cazzola,Jaroslav Cermak,Christa Fonatsch,Michelle M. Le Beau,Marilyn L. Slovak,Otto Krieger,Michael Luebbert,Jaroslaw P. Maciejewski,Silvia Maria Meira Magalhães,Yasushi Miyazaki,Michael Pfeilstöcker,Mikkael A. Sekeres,Wolfgang R. Sperr,Reinhard Stauder,Sudhir Tauro,Peter Valent,Teresa Vallespi,Arjan A. van de Loosdrecht,Ulrich Germing,Detlef Haase +33 more
TL;DR: This revised IPSS-R comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS and should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.
2.9K
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma,Rafael Bejar,Siddhartha Jaiswal,R. Coleman Lindsley,Mikkael A. Sekeres,Robert P. Hasserjian,Benjamin L. Ebert +6 more
TL;DR: The nature and prevalence of CHIP, distinction of this state from MDS, and current areas of uncertainty regarding diagnostic criteria for myeloid malignancies are discussed.
1.7K
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Hagop Kantarjian,J. Issa,Craig S. Rosenfeld,John M. Bennett,Maher Albitar,John DiPersio,Virginia Klimek,James Slack,Carlos de Castro,Farhad Ravandi,Richard Helmer,Lanlan Shen,Stephen D. Nimer,Richard Leavitt,Azra Raza,Hussain Saba +15 more
TL;DR: Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy.
1.5K
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
John S. Welch,Allegra A. Petti,Christopher A. Miller,Catrina Fronick,Michelle O'Laughlin,Robert S. Fulton,Richard K. Wilson,Jack Baty,Eric J. Duncavage,Bevan Tandon,Yi-Shan Lee,Lukas D. Wartman,Geoffrey L. Uy,Armin Ghobadi,Michael H. Tomasson,Iskra Pusic,Rizwan Romee,Todd A. Fehniger,Keith Stockerl-Goldstein,Ravi Vij,Stephen T. Oh,Camille N. Abboud,Amanda F. Cashen,Mark A. Schroeder,Meagan A. Jacoby,Sharon Heath,Kierstin Luber,Megan Janke,Andrew Hantel,Niloufer Khan,Madina Sukhanova,Randall W. Knoebel,Wendy Stock,Timothy A. Graubert,Matthew J. Walter,Peter Westervelt,Daniel C. Link,John F. DiPersio,Timothy J. Ley +38 more
TL;DR: Patients with AML and MDS who had cytogenetic abnormalities associated with unfavorable risk, TP53 mutations, or both had favorable clinical responses and robust (but incomplete) mutation clearance after receiving serial 10-day courses of decitabine.
760